Sector
PharmaceuticalsOpen
₹394.75Prev. Close
₹393.75Turnover(Lac.)
₹569.48Day's High
₹415.9Day's Low
₹365.4552 Week's High
₹504.2552 Week's Low
₹277.65Book Value
₹57.36Face Value
₹1Mkt Cap (₹ Cr.)
4,141.46P/E
46.61EPS
8.47Divi. Yield
0.03Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 10.03 | 9.69 | 9.69 | 9.69 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 522.53 | 338.11 | 259.42 | 163.74 |
Net Worth | 532.56 | 347.8 | 269.11 | 173.43 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 779.15 | 487.69 | 357.75 | 300.96 |
yoy growth (%) | 59.76 | 36.32 | 18.86 | 22.58 |
Raw materials | -411.96 | -250.29 | -177.47 | -142.22 |
As % of sales | 52.87 | 51.32 | 49.6 | 47.25 |
Employee costs | -85.61 | -66.21 | -51.57 | -44.46 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 126.83 | 57.71 | 30.33 | 27.95 |
Depreciation | -17.13 | -16.3 | -8.35 | -4.3 |
Tax paid | -30.99 | -13.47 | -7.47 | -13.51 |
Working capital | 30.22 | -13.96 | 33.14 | 35.94 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 59.76 | 36.32 | 18.86 | 22.58 |
Op profit growth | 73.63 | 88.23 | 16.83 | 66.26 |
EBIT growth | 84.57 | 65.73 | 16.98 | 77.7 |
Net profit growth | 116.67 | 93.51 | 42.66 | 77.6 |
Particulars (Rupees in Crores.) | Mar-2024 |
---|---|
Gross Sales | 806.67 |
Excise Duty | 0 |
Net Sales | 806.67 |
Other Operating Income | 0 |
Other Income | 2.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,699.75 | 129.46 | 4,07,826.96 | 1,181.05 | 0.79 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,946.75 | 76.18 | 1,57,931.24 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,453.15 | 25.21 | 1,17,322.09 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,106.5 | 57.61 | 1,05,080.9 | 485 | 0.9 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,450.3 | 52.3 | 1,01,134.59 | 416.38 | 0 | 2,396.57 | 334.18 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Jayesh P Choksi
Whole Time Director & CEO
Pranav J Choksi
Whole-time Director
Pankaj Gandhi
Company Sec. & Compli. Officer
Ami Naresh Shah
Non-Exec. & Independent Dir.
Shrirang V Vadiya
Non-Exec & Non-Independent Dir
Balram Singh
Non-Exec. & Independent Dir.
Rabi Narayan Sahoo
Non-Exec. & Independent Dir.
Anusanjiv Aurora
Whole-time Director
Dilip Ghosh
Non-Exec. & Independent Dir.
Kamal Kishore Seth
Additional Director
Akshya Kumar Mahapatra
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gufic BioSciences Ltd
Summary
Gufic Biosciences (GBL) was incorporated in Jul84. The Company is a result of a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 40-42 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Choksi and Gandhi family, the promoters of GBL, have a long-standing presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets. Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil.In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held.Gufic has divested brands in the ethical pharma business in a sellers market.
Read More
The Gufic BioSciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹413 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gufic BioSciences Ltd is ₹4141.46 Cr. as of 12 Feb ‘25
The PE and PB ratios of Gufic BioSciences Ltd is 46.61 and 6.89 as of 12 Feb ‘25
The 52-week high/low is the highest and lowest price at which a Gufic BioSciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gufic BioSciences Ltd is ₹277.65 and ₹504.25 as of 12 Feb ‘25
Gufic BioSciences Ltd's CAGR for 5 Years at 38.85%, 3 Years at 21.04%, 1 Year at 21.17%, 6 Month at 9.89%, 3 Month at -13.37% and 1 Month at -17.37%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.